NLRP3 and idiopathic inflammatory myopathy: These results suggest that the NLRP3 inflammasome-mediated IL-1β/IL-18 pathway plays a role in the pathogenesis of idiopathic inflammatory myopathy, and glyburide inhibiting this pathway leads to reduced secretion of inflammatory factors, alleviation of inflammation, and improvement in muscle strength.